Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Serum Zinc Level and Coronary Heart Disease Events in Patients With Type 2 Diabetes
Diabetes Care, 03/05/07
Soinio, M., et al. – Low serum zinc level a risk factor for CHD events in this diabetic population.
>Summary: Serum zinc values were obtained from a group of 1,059 patients with type 2 diabetes, aged 45 - 64 years. Mean duration of diabetes was 8 years. CHD mortality and the incidence of nonfatal MI were assessed in a 7-year follow-up.
Outcomes: Patients with a serum zinc concentration of lower 14.1 µmol/l at baseline had a higher risk for death from CHD than patients with serum zinc level above 14.1 µmol/l. The risks for fatal or nonfatal MI were 30.5 and 22.0%, respectively. A Cox regression analyses determined that low serum zinc concentration was significantly associated with CHD mortality and all CHD events even after adjustment for confounding variables
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation
European Journal of Clinical Investigation, 06/01/09
Valsartan for Prevention of Recurrent Atrial Fibrillation
New England Journal of Medicine, 04/16/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
A randomized trial of therapies for type 2 diabetes and coronary artery disease
New England Journal of Medicine, 06/10/09
Sponsor
Article Search
Sponsor


See Latest Articles


